Currently, there are 773.28M common shares owned by the public and among those 325.95M shares have been available to trade.
The company’s stock has a 5-day price change of 9.59% and 12.68% over the past three months. OPK shares are trading 5.96% year to date (YTD), with the 12-month market performance up to 30.08% higher. It has a 12-month low price of $0.85 and touched a high of $1.75 over the same period. OPK has an average intraday trading volume of 3.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.40%, 4.17%, and 23.62% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Opko Health Inc (NASDAQ: OPK) shares accounts for 29.33% of the company’s 773.28M shares outstanding.
It has a market capitalization of $1.12B and a beta (3y monthly) value of 1.65. The earnings-per-share (ttm) stands at -$0.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.37% over the week and 4.40% over the month.
Earnings per share for the fiscal year are expected to decrease by -20.67%, and 4.97% over the next financial year. EPS should grow at an annualized rate of 12.00% over the next five years, compared to 1.56% over the past 5-year period.
Looking at the support for the OPK, a number of firms have released research notes about the stock. Barrington Research stated their Outperform rating for the stock in a research note on June 29, 2023, with the firm’s price target at $2. H.C. Wainwright coverage for the Opko Health Inc (OPK) stock in a research note released on December 15, 2022 offered a Buy rating with a price target of $3. Barrington Research was of a view on January 24, 2022 that the stock is Mkt Perform, while Ladenburg Thalmann gave the stock Buy rating on June 21, 2021, issuing a price target of $7. Piper Jaffray on their part issued Overweight rating on November 25, 2019.
